Venlafaxine, but not mirtazapine lowers retinol-binding protein 4 serum concentrations in nondiabetic depressed patients.
Deuschle
M
M
Angermeier
T
T
Westphal
S
S
Lederbogen
F
F
Gilles
M
M
Frankhauser
P
P
Schilling
C
C
Onken
V
V
Weber-Hamann
B
B
Kopf
D
D
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000097:blood* / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D054839:Retinol-Binding Proteins, Plasma / Q000378:metabolism*; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma; D008803:Mianserin; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine